First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients
Elisabeth Silkenstedt(LMU Klinikum), M. Dreyling(LMU Klinikum)
Cited by 3
Related Papers
Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis
|JNCI Journal of the National Cancer Institute|2007|366
Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2024|46
Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2024|11